4.2 Review

Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies

Journal

EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 108, Issue 5, Pages 359-368

Publisher

WILEY
DOI: 10.1111/ejh.13751

Keywords

anti-CD20; anti-PD1; follicular lymphoma; hematological malignancy; immunosuppressant; nivolumab; pembrolizumab; PML; targeted therapy

Categories

Ask authors/readers for more resources

This paper presents a case of a patient with follicular lymphoma treated with anti-CD20 monoclonal antibody-based regimens and diagnosed with progressive multifocal leukoencephalopathy (PML). Despite treatment with nivolumab, the patient ultimately succumbed to the disease. The paper focuses on reviewing PML cases related to newer agents used in hematology and discussing factors affecting prognosis as well as upcoming therapeutic options.
Progressive multifocal leukoencephalopathy (PML) is a rare, often fatal demyelinating disease of the central nervous system (CNS) caused by the reactivation of JC polyomavirus in the CNS. We present a case of a 54-year-old man with follicular lymphoma diagnosed with PML after being treated with anti-CD20 monoclonal antibody-based regimens for several years. Due to the lack of effective treatment choices for PML, the patient was treated with nivolumab, based on recent reports, but succumbed to his disease a few months after diagnosis. In this paper, we focus on reviewing the literature of PML cases correlated with newer agents used in hematology, possible factors affecting disease prognosis, as well as the available data on upcoming therapeutic options for patients with PML. Though newer promising treatments such as anti-PD1 monoclonal antibodies arise, a definitive treatment option is yet to be found. Vigilance, early detection, and prompt intervention play a crucial role in the prognosis of PML in patients with hematological malignancies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available